Obesity – significant medical and social problem of our time: risk factors, pathophysiological determinants, treatment strategies. A review
- Authors: Biryukova E.V.1
-
Affiliations:
- Russian University of Medicine
- Issue: Vol 26, No 7 (2024): Women's and men's health
- Pages: 461-469
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/270515
- DOI: https://doi.org/10.26442/20751753.2024.7.203014
- ID: 270515
Cite item
Full Text
Abstract
Obesity is a chronic multifactorial recurrent condition with serious health consequences that contributes significantly to the morbidity and mortality in the population. A positive energy balance, which occurs when food is consumed in an amount exceeding the energy consumption or when energy consumption is reduced, is considered one of the main mechanisms of obesity. The most common type of obesity is exogenous (alimentary-constitutional). There are various pathophysiological determinants of obesity, with adipose tissue playing the most significant role. Non-pharmacological therapies, including lifestyle changes through nutritional correction and increase in physical activity, behavioral therapies aimed at preventing or treating eating disorders, are recommended as the first, mandatory, and continuous stage of obesity treatment. However, the use of non-pharmacological interventions alone is often limited by insufficient effectiveness. Fonturacetam has a promising potential for use in the fight against obesity. The mechanisms of fonturacetam influence on body weight control, energy homeostasis, carbohydrate and fat metabolism, anorexigenic and anti-inflammatory effects showed in studies are the key factors determining the prospects of fonturacetam use in the complex therapy of obesity.
Full Text
##article.viewOnOriginalSite##About the authors
Elena V. Biryukova
Russian University of Medicine
Author for correspondence.
Email: lena@obsudim.ru
ORCID iD: 0000-0001-9007-4123
D. Sci. (Med.)
Russian Federation, MoscowReferences
- Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288-98. doi: 10.1038/s41574-019-0176-8
- Malik VS, Willet WC, Hu FB. Nearly a decade on – trends, risk factors and policy implications in global obesity. Nat Rev Endocrinol. 2020;16(11):615-1. doi: 10.1038/s41574-020-00411-y
- Ожирение и избыточная масса тела. Режим доступа: https://www.who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight. Ссылка активна на 01.08.2024 [Ozhirenie i izbytochnaia massa tela. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight. Accessed: 01.08.2024 (in Russian)].
- Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011;377(9765):557-67. doi: 10.1016/S0140-6736(10)62037-5
- Simmonds M, Llewellyn A, Owen CG, Woolacott N. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev. 2016;17(2):95-107. doi: 10.1111/obr.12334
- Фурсов А.Б., Оспанов О.Б., Фурсов Р.А. Ожирение и COVID-19 – признаки конвергенции двух пандемий. Рекомендации по борьбе с ожирением, основанные на принципах «ROOTS». Ожирение и метаболизм. 2021;18(4):456-64 [Fursov AB, Ospanov OB, Fursov RA. Obesity and COVID-19 – signs of convergence of two pandemiсs. Guidelines to fight obesity based on the principles of «ROOTS». Obesity and Metabolism. 2021;18(4):456-64 (in Russian)]. doi: 10.14341/omet12745
- Wise J. Covid-19: Highest death rates seen in countries with most overweight populations. BMJ. 2021;372:n623. doi: 10.1136/bmj.n623
- Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715-23. doi: 10.1111/obr.12551
- Sbraccia P, Dicker D. Obesity is a chronic progressive relapsing disease of particular interest for internal medicine. Intern Emerg Med. 2023;18(1):1-5. doi: 10.1007/s11739-022-03129-z
- Разина А.О., Руненко С.Д., Ачкасов Е.Е. Проблема ожирения: современные тенденции в России и в мире. Вестник Российской академии медицинских наук. 2016;71(2):154-9 [Razina AO, Runenko SD, Achkasov EE. Obesity: Current Global and Russian Trends. Annals of the Russian Academy of Medical Sciences. 2016;71(2):154-9 (in Russian)]. doi: 10.15690/vramn655
- Klein S, Gastaldelli A, Yki-Järvinen H, Scherer PE. Why does obesity cause diabetes? Cell Metab. 2022;34(1):11-20. doi: 10.1016/j.cmet.2021.12.012
- Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., и др. Ожирение. Клинические рекомендации. Consilium Medicum. 2021;23(4):311-25 [Dedov II, Mokrysheva NG, Mel’nichenko GA, et al. Obesity. Clinical guidelines. Consilium Medicum. 2021;23(4):311-25 (in Russian)]. doi: 10.26442/20751753.2021.4.200832
- Dedov I, Shestakova M, Benedetti MM, et al. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res Clin Pract. 2016;115:90-5. doi: 10.1016/j.diabres.2016.02.010
- Bjerregaard LG, Jensen BW, Ängquist L, et al. Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes. N Engl J Med. 2018;378(14):1302-32. doi: 10.1056/NEJMoa1713231
- Weiss F, Barbuti M, Carignani G, et al. Psychiatric Aspects of Obesity: A Narrative Review of Pathophysiology and Psychopathology. J Clin Med. 2020;9(8). doi: 10.3390/jcm9082344
- O'Brien PD, Hinder LM, Callaghan BC, Feldman EL. Neurological consequences of obesity. Lancet Neurol. 2017;16(6):465-77. doi: 10.1016/S1474-4422(17)30084-4
- Leutner M, Dervic E, Bellach L, et al. Obesity as pleiotropic risk state for metabolic and mental health throughout life. Transl Psychiatry. 2023;13(1):175. doi: 10.1038/s41398-023-02447-w
- Heuschmann PU, Kircher J, Nowe T, et al. Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. Eur J Prev Cardiol. 2015;22(10):1354-62. doi: 10.1177/2047487314546825
- Jin X, Qiu T, Li L, et al. Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B. 2023;13(6):2403-44. doi: 10.1016/j.apsb.2023.01.012
- Выборная К.В., Соколов А.И., Кобелькова И.В., и др. Основной обмен как интегральный количественный показатель интенсивности метаболизма. Вопросы питания. 2017;86(5):5-10 [Vybornaya KV, Sokolov AI, Kobelkova IV, et al. Basal metabolic rate as an integral indicator of metabolism intensity. Voprosy Pitaniia = Problems of Nutrition. 2017;86(5):5-10 (in Russian)]. doi: 10.24411/0042-8833-2017-00069.
- Levine JA. Measurement of energy expenditure. Public Health Nutr. 2005;8(7A):1123-32. doi: 10.1079/phn2005800
- Henry CJ. Basal metabolic rate studies in humans: measurement and development of new equations. Public Health Nutr. 2005;8(7A):1133-52. doi: 10.1079/phn2005801
- Pontzer H, Yamada Y, Sagayama H, et al. Daily energy expenditure through the human life course. Science. 2021;373(6556):808-12. doi: 10.1126/science.abe5017
- Васюкова О.В., Окороков П.Л., Касьянова Ю.В., Безлепкина О.Б. Энергетический обмен человека: как мы можем персонифицировать терапию ожирения. Проблемы Эндокринологии. 2021;67(5):4-10 [Vasyukova OV, Okorokov PL, Kasyanova YuV, Bezlepkina OB. Energy exchange: how we can personalize obesity therapy. Problems of Endocrinology. 2021;67(5):4-10 (in Russian)]. doi: 10.14341/probl12830
- Kodoth V, Scaccia S, Aggarwal B. Adverse Changes in Body Composition During the Menopausal Transition and Relation to Cardiovascular Risk: A Contemporary Review. Womens Health Rep (New Rochelle). 2022;3(1):573-81. doi: 10.1089/whr.2021.0119
- Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc. 2001;60(3):349-56. doi: 10.1079/pns2001110
- Романцова Т.И. Жировая ткань: цвета, депо и функции. Ожирение и метаболизм. 2021;18(3):282-301 [Romantsova TI. Adipose tissue: colors, depots and functions. Obesity and Metabolism. 2021;18(3):282-301 (in Russian)]. doi: 10.14341/omet12748
- Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014;63(4):250-9. doi: 10.1016/j.jjcc.2013.11.006
- Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci. 2015;36(7):461-70. doi: 10.1016/j.tips.2015.04.014
- Wondmkun YT. Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab Syndr Obes. 2020;13:3611-66. doi: 10.2147/DMSO.S275898
- Michailidou Z, Gomez-Salazar M, Alexaki VI. Innate Immune Cells in the Adipose Tissue in Health and Metabolic Disease. J Innate Immun. 2022;14(1):4-30. doi: 10.1159/000515117
- Романцова Т.И. Иммунометаболизм и метавоспаление при ожирении. Ожирение и метаболизм. 2016;16(4):3-17 [Romantsova TR, Sych YuP. Immunometabolism and metainflammation in obesity. Obesity and Metabolism. 2019;16(4):3-17 (in Russian)]. doi: 10.14341/omet12218
- Zhao S, Kusminski CM, Elmquist JK, Scherer PE. Leptin: Less Is More. Diabetes. 2020;69(5):823-2. doi: 10.2337/dbi19-0018
- Попов М.Ю., Лепик О.В., Козловский В.Л., Попов Ю.В. Фармакологические стратегии модуляции аппетита при расстройствах пищевого поведения: нарративный обзор литературы. Consortium Psychiatricum. 2023;4(2):79-90 [Popov MY, Lepik OV, Kozlovskii VL, Popov YV. Pharmacological strategies for appetite modulation in eating disorders: a narrative review. Consortium Psychiatricum. 2023;4(2):79-90 (in Russian)]. doi: 10.17816/CP6150
- Sainsbury A, Cooney GJ, Herzog H. Hypothalamic regulation of energy homeostasis. Best Pract Res Clin Endocrinol Metab. 2002;16(4):623-37. doi: 10.1053/beem.2002.0230
- Brown SSG, Westwater ML, Seidlitz J, et al. Hypothalamic volume is associated with body mass index. Neuroimage Clin. 2023;39:103478. doi: 10.1016/j.nicl.2023.103478
- Kullmann S, Valenta V, Wagner R, et al. Brain insulin sensitivity is linked to adiposity and body fat distribution. Nat Commun. 2020;11(1):1841. doi: 10.1038/s41467-020-15686-y
- Guillemot-Legris O, Muccioli GG. Obesity-Induced Neuroinflammation: Beyond the Hypothalamus. Trends Neurosci. 2017;40(4):237-53. doi: 10.1016/j.tins.2017.02.005
- Seong J, Kang JY, Sun JS, Kim KW. Hypothalamic inflammation and obesity: a mechanistic review. Arch Pharm Res. 2019;42(5):383-92. doi: 10.1007/s12272-019-01138-9
- De Souza CT, Araujo EP, Bordin S, et al. Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology. 2005;146(10):4192-9. doi: 10.1210/en.2004-1520
- Davidson TL, Monnot A, Neal AU, et al. The effects of a high-energy diet on hippocampal-dependent discrimination performance and blood-brain barrier integrity differ for diet-induced obese and diet-resistant rats. Physiol Behav. 2012;107(1):26-33. doi: 10.1016/j.physbeh.2012.05.015
- Sewaybricker LE, Huang A, Chandrasekaran S, et al. The Significance of Hypothalamic Inflammation and Gliosis for the Pathogenesis of Obesity in Humans. Endocr Rev. 2023;44(2):281-96. doi: 10.1210/endrev/bnac023
- Bandala C, Cárdenas-Rodríguez N, Reyes-Long S, et al. Trends in Gliosis in Obesity, and the Role of Antioxidants as a Therapeutic Alternative. Antioxidants (Basel). 2022;11(10). doi: 10.3390/antiox11101972
- Rosenbaum JL, Melhorn SJ, Schoen S, et al. Evidence That Hypothalamic Gliosis Is Related to Impaired Glucose Homeostasis in Adults With Obesity. Diabetes Care. 2022;45(2):416-24. doi: 10.2337/dc21-1535
- Berkseth KE, Rubinow KB, Melhorn SJ, et al. Hypothalamic Gliosis by MRI and Visceral Fat Mass Negatively Correlate with Plasma Testosterone Concentrations in Healthy Men. Obesity (Silver Spring). 2018;26(12):1898-904. doi: 10.1002/oby.22324
- Rossi F, Punzo F, Umano GR, et al. Role of Cannabinoids in Obesity. Int J Mol Sci. 2018;19(9). doi: 10.3390/ijms19092690
- Дударева В.А., Шикалева А.А., Максимов М.Л., и др. Роль эндоканнабиноидной системы в развитии ожирения. РМЖ. 2020;1:23-8 [Dudareva VA, Shikaleva AA, Maksimov ML, et al. Rol' endokannabinoidnoi sistemy v razvitii ozhireniia. RMZh. 2020;1:23-8 (in Russian)].
- Бакулина Н.В., Тихонов С.В., Ермоленко Е.И., и др. Кишечная микробиота, гастроэнтерологические жалобы и качество жизни у пациентов с избыточной массой тела, ожирением и сахарным диабетом 2-го типа. Профилактическая медицина. 2022;25(6):80-8 [Bakulina NV, Tikhonov SV, Ermolenko EI, et al. Intestinal microbiota, gastroenterological complaints and quality of life in overweight, obese and type 2 diabetes patients. Russian Journal of Preventive Medicine. 2022;25(6):80-8 (in Russian)]. doi: 10.17116/profmed2022250618
- Mulders RJ, de Git KCG, Schéle E, et al. Microbiota in obesity: interactions with enteroendocrine, immune and central nervous systems. Obes Rev. 2018;19(4):435-51. doi: 10.1111/obr.12661
- Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab. 2014;16(1):9-21. doi: 10.1111/dom.12119
- Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351. doi: 10.1016/j.molmet.2021.101351
- Durrer Schutz D, Busetto L, Dicker D, et al. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019;12(1):40-66. doi: 10.1159/000496183
- Chakhtoura M, Haber R, Ghezzawi M, et al. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58:101882. doi: 10.1016/j.eclinm.2023.101882
- Magkos F, Fraterrigo G, Yoshino J, et al. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell Metab. 2016;23(4):591-601. doi: 10.1016/j.cmet.2016.02.005
- Струева Н.В., Гегель Н.В., Полуэктов М.Г., и др. Особенности психического состояния больных с ожирением в зависимости от сопутствующих нарушений сна. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;114(11):88-91 [Strueva NV, Gegel' NV, Poluektov MG, et al. Features of the mental state of obese patients with concomitant sleep disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11):88-91 (in Russian)].
- Путилина М.В. Эффективная нейромодуляция как основа современной нейропротекции в терапии сосудистых заболеваний нервной системы. Нервные болезни. 2022;1:72-6 [Putilina MV. Effektivnaia neiromoduliatsiia kak osnova sovremennoi neiroprotektsii v terapii sosudistykh zabolevanii nervnoi sistemy. Nervnye bolezni. 2022;1:72-6 (in Russian)]. doi: 10.24412/2226-0757-2022-12413
- Zvejniece L, Svalbe B, Vavers E, et al. S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity. Pharmacol Biochem Behav. 2017;160:21-9. doi: 10.1016/j.pbb.2017.07.009
- Коздоба А., Максимов М.Л. Новые свойства ноотропного препарата «Фонтурацетам». Терапевт. 2022;12 [Kozdoba A, Maksimov ML. Novye svoistva nootropnogo preparata “Fonturatsetam”. Terapevt. 2022;12 (in Russian)].
- Громова О.А., Торшин И.Ю. Хемореактомное исследование эффектов препарата Актитропил (фонтурацетам): молекулярные механизмы влияния на метаболизм жировой ткани. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2024;17(2):172-81 [Gromova OA, Torshin IYu. Chemoreactomic study of fonturacetam effects: molecular mechanisms of influence on adipose tissue metabolism. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2024;17(2):172-81 (in Russian)].
- Zvejniece L, Zvejniece B, Videja M, et al. Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice. Inflammopharmacology. 2020;28(5):1283-22. doi: 10.1007/s10787-020-00705-7
- Тюренков И.Н., Самотруева М.А., Цибизова А.А., Ясенявская А.Л. Фенотропил как модулятор уровня цитокинов в условиях экспериментальной иммунопатологии. Экспериментальная и клиническая фармакология. 2015;78(12):15-7 [Tyurenkov IN, Samotrueva MA, Tsibizova AA, Yasenyavskaya AL. Phenotropil as modulator of cytokine level under conditions of experimental immunopathology. Eksperimental'naia i klinicheskaia farmakologiia. 2015;78(12):15-7 (in Russian)].
- Енькова Е.В., Минаев Н.Н. Изучение эффективности препарата Фенотропил в качестве корректора веса в дополнение к диетотерапии у женщин репродуктивного возраста с нарушением менструального цикла, ожирением алиментарно-конституционального типа и цефалгией. В: I Всероссийский конгресс молодых ученых в области медицины и биологии по итогам конкурса «Свет знаний во имя здоровья человека». Сборник научных трудов. Под ред. В.И. Ахапкиной. М. 2009 [En'kova EV, Minaev NN. Izuchenie effektivnosti preparata Fenotropil v kachestve korrektora vesa v dopolnenie k dietoterapii u zhenshchin reproduktivnogo vozrasta s narusheniem menstrual'nogo tsikla, ozhireniem alimentarno-konstitutsional'nogo tipa i tsefalgiei. In: I Vserossiiskii kongress molodykh uchenykh v oblasti meditsiny i biologii po itogam konkursa “Svet znanii vo imia zdorov'ia cheloveka”. Sbornik nauchnykh trudov. Pod red. VI Akhapkinoi. Moscow. 2009 (in Russian)].
Supplementary files
